Facebook
Twitter
LinkedIn
Forward2025 Endocrinology Grand Rounds | Management of Advanced Paraganglioma and Pheochromocytoma Tumors
Advanced paraganglioma and pheochromocytoma tumors is a challenging topic in the field of endocrinology, which often result in acute coronary syndromes, and strokes, among other adverse outcomes. Improving detection, prevention, and identification of genetic susceptibility genes in these patients is imperative seek improvement in patient outcomes.
The field of endocrine tumor care in endocrinology has always been a difficult and challenging area. Care for this patient population requires the latest knowledge of gemomic and systemic therapies available. Despite several recent advances in diagnosis, localization, and management, pheochromocytomas and paragangliomas continue to have significant morbidity and mortality. There is a need to stay abreast on updates and the latest treatments, in order to manage these patients better and increase the quality of care for this population.
Target Audience
Physicians and endocrinologists.
Learning Objectives
- Discuss initial evaluation of advanced paraganglioma and pheochromocytoma cases.
- Examine the genetic analysis of these tumors.
- Outline different treatment modalities for metastatic paraganglioma and pheochromocytoma cases.
Virtual Meeting- Zoom
Sasan Fazeli, MD Assistant Clinical Professor, Department of Endocrinology, City of Hope
Presenter: Dr. Fazeli has indicated the following relevant financial relationships: Consultant for Genentech, Inc. and Novartis.
Planner: Pooja Manroa, MD has indicated that there are no relevant financial relationships with ineligible companies.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2025 Endocrinology Grand Rounds | Management of Advanced Paraganglioma and Pheochromocytoma Tumors for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance